Arylazoamidoximes and related compounds as NO-modulators

Archiv der Pharmazie
Alexander SchröderKlaus Rehse

Abstract

Three amidinoarylhydrazines 1, three arylazoamidines 2, and nine arylazoamidoximes 3 have been synthesized and investigated for their potential to function as nitric oxide (NO) modulators. In-vitro studies demonstrated that 2 and 3 inhibited platelet aggregation (2c, IC(50 )= 3 microM) which could also be shown in vivo by inhibition of thrombus formation in arterioles (3a, 22%). Moreover, for all compounds antihypertensive effects were examined in vivo with SHR rats, with 2a being the most potent candidate by lowering blood pressure by 19%. However, no common underlying mechanism of action could be shown. Some of these compounds released HNO non-enzymatically. Incubations with NO synthase isoforms (NOSs) revealed, that compounds 1 to 3 were weak substrates for NOSs but arylazoamidoximes 3 remarkably elevated the NOSs activity in the presence of L-arginine (3h, up to fivefold). In addition, we examined effects on arginase and dimethylarginine dimethylaminohydrolase (DDAH), two further enzymes involved in the complex regulation of NO biosynthesis, to elucidate whether the observed in-vivo effects can be traced back to their modulation. Furthermore, the metabolic fate of arylazoamidoximes 3 was addressed by investigation of a poss...Continue Reading

References

Jan 1, 1980·British Journal of Clinical Pharmacology·P A van Zwieten
Jan 1, 1994·Methods in Enzymology·J M Hevel, M A Marletta
Sep 15, 1999·Cellular and Molecular Life Sciences : CMLS·J L BoucherJ P Tenu
Dec 4, 2002·Nature Reviews. Drug Discovery·Patrick Vallance, James Leiper
Jul 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Katrina M MirandaDavid A Wink
May 4, 2005·Pharmacology & Therapeutics·Noboru TodaTomio Okamura
Apr 4, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·P FerroniG Davì
Sep 9, 2006·Biochemical and Biophysical Research Communications·Bernd ClementSabine Heberling
Dec 16, 2006·The Journal of Clinical Hypertension·Leopoldo Raij
Dec 18, 2007·Bioorganic & Medicinal Chemistry·Jürke KotthausBernd Clement
Oct 7, 2008·Trends in Pharmacological Sciences·Jennifer C IrvineBarbara K Kemp-Harper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.